Submit Deal

COMMODORE CAPITAL

HQ - New York, NY

Summary

Commodore Capital is invested in the early stages of a major innovation cycle in biopharmaceuticals.

Deals Overview

Total Deals7

Valued Deals7

Total Value£ 946 M

Avg. Deal Size£ 135 M

Market Context

Senior Management

Michael Kramarz
Managing Partner
Egen Atkinson
Founding Partner

Sort

kronos bio

HQ - United States

Pharmaceuticals

24 Aug 2020

Investment Date

£ 118 M

Deal Value

c4 therapeutics inc

HQ - United States

Biotechnology

16 Jun 2020

Investment Date

£ 119 M

Deal Value

miragen therapeutics

HQ - United States

Biotechnology

28 Oct 2020

Investment Date

£ 70 M

Deal Value

shoreline biosciences

HQ - United States

Biotechnology

2 Nov 2021

Investment Date

£ 102 M

Deal Value

idrx

HQ - United States

Biotechnology

7 Aug 2024

Investment Date

£ 94 M

Deal Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy